IP Library Patent Application 16569162
Patent Application
App. No. 16/569,162

COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/569,162
Abstract

The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.

Claims (16)

1 - 73 . (canceled)

74 . A method for treating rheumatoid arthritis in a subject comprising administering to the subject an antibody which binds to CD38 and comprises light and heavy chain variable region CDRs set forth in SEQ ID NOs: 13, 14, and 15 and SEQ ID NOs: 18, 19, and 20, respectively.

75 . A method for treating rheumatoid arthritis in a subject comprising administering to the subject an antibody which binds to CD38 and comprises light and heavy chain variable region sequences which are at least 90% identical to SEQ ID NOs: 12 and 17, respectively.

76 . The method of claim 74 , wherein the antibody is internalized by CD38 expressing cells.

77 . The method of claim 74 , wherein said antibody does not induce release of significant IL-6 by human monocytes or peripheral blood mononuclear cells.

78 . The method of claim 74 , wherein said antibody does not induce release of detectable IFN-γ by human T cells or peripheral blood mononuclear cells.

79 . The method of claim 74 , wherein the antibody is a monoclonal antibody.

80 . The method of claim 74 , wherein the antibody is a human monoclonal antibody.

81 . The method of claim 74 , wherein the antibody is a full length IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM antibody.

82 . The method of claim 74 , wherein the antibody is an antibody fragment or a single-chain antibody.

83 . The method of claim 74 , wherein the antibody is conjugated to a cytotoxic agent, a radioisotope, or a drug.

84 . The method of claim 74 , further comprising administering at least one corticosteroid.

85 . The method of claim 74 , further comprising administering an anti-inflammatory agent.

86 . The method of claim 74 , further comprising administering an immunosuppressive agent.

87 . The method of claim 74 , further comprising administering an immunomodulatory agent.

88 . A method for treating multiple myeloma in a subject comprising administering to the subject an antibody which binds to CD38 and comprises light and heavy chain variable region CDRs set forth in SEQ ID NOs: 13, 14, and 15 and SEQ ID NOs: 18, 19, and 20, respectively.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2020
From: VAN DE WINKEL, JAN; PARREN, PAUL; GRAUS, YVO; OPRINS, JUDITH; DE WEERS, MICHEL; VAN VUGT, MARTINE; BAADSGAARD, OLE; LISBY, STEEN
To: GENMAB A/S
Reel/Frame 051405/0667 →